Abpro and Celltrion announce FDA IND clearance for lead multispecific antibody ABP-102 / CT-P72

Abpro Holdings, Inc.

FDA cleared IND for ABP-102 / CT-P72, a multispecific HER2 × CD3 T-cell engager targeting HER2-positive solid tumors.
Phase 1 clinical trial anticipated to commence in H1 2026, led by Celltrion under co-development collaboration.
Preclinical data showed selective antitumor activity in HER2-high models and was well tolerated in NHP studies up to 80 mg/kg.
Candidate designed to enhance tumor selectivity and limit activity in HER2-low tissues, aiming to reduce cytokine release syndrome risk.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.